News
Home / News
News
Dymicron® is proud to be recognized in the annual listing of 10 companies at the forefront of providing biomechanics solutions impacting the industry
“Dymicron® next-generation Triadyme-C Artificial Cervical Disc solves the domain’s two greatest challenges: the replication of natural spine motion and the elimination of wear debris
News
Dymicron® Wins 2021 Best New Spine Technology Award from Orthopedics This Week for the Triadyme® – C Artificial Cervical Disc
“Dymicron® today announced its Triadyme – C Artificial Cervical Disc won the 2021 Best New Spine Technology Award presented by Orthopedics This Week, a widely read publication in the orthopedics industry. The Award will be presented at the North American Spine Society (NASS) Annual Meeting in Boston on September 29th.
News
Man-made Diamond Leads the Way in Next-Generation Cervical Disc Replacement Device
“Dymicron® is a privately-held medical device company that has developed a next-generation man-made diamond material for orthopaedic applications. Dymicron is using this material in its artificial cervical disc replacement system, Triadyme®-C. Recently, we caught up with Dymicron’s Chief Strategy Officer, Ted Bird, to find out more about the company and the application of their innovative material to their device’s unique Tri-Lobe design.”
ghp Healthcare & Pharmaceutical Awards
News
Dymicron®Names Gunther Peeters as Senior Vice President of Commercial Operations
“We are very pleased to have Gunther join our leadership team,” said Alan Layton Chairman and CEO of Dymicron. “As we advance our commercial activities in key international markets, Gunther’s expertise in cervical arthroplasty and extensive network of relationships in the spine industry will help us achieve our commercial goals and support our strategic initiatives.”
News
Dymicron® appoints Armen Khachatryan, M.D. to Board of Directors
“We are delighted to welcome Dr. Khachatryan to Dymicron’s Board,” said Alan Layton Chairman and CEO of Dymicron. “Dr. Khachatryan’s highly accomplished track record and vast experience with cervical arthroplasty will be tremendously helpful to our company as we prepare for FDA clinical trials in the US and commercialization in select countries outside the US with our CE Mark.”
